The boston criteria v.2.0 incorporate emerging mri markers of caa to enhance sensitivity without compromising their specificity. We performed a retrospective analysis of clinical, radiological, and histopathological data available to sites participating in the international caa association to formulate and determine. Future use of the v.2.0 criteria will determine.
We report an international collaborative study aiming to update and externally validate the boston diagnostic criteria across the full spectrum of clinical caa presentations. The aim of this review is to demonstrate the diagnostic criteria for caa with an emphasis on typical imaging findings which are part of the boston criteria 2.0 and other. The boston criteria version 2.0 [1] is a set of guidelines designed to diagnose cerebral amyloid angiopathy (caa), a disease that affects small blood vessels in the brain, particularly those in.
You can read and download a pdf full text of this paper here. As the boston criteria for cerebral amyloid angiopathy were last updated in 2010 (v1.5), a new multicentre study based on neuropathological and neuroimaging findings was. We report an international collaborative study aiming to update and externally validate the boston diagnostic criteria across the full spectrum of clinical caa presentations.